starting tirzepatide after semaglutide Switching to Tirzepatide: A Provider's Guide Switching Semaglutide to Tirzepatide |

ATTAIN-1 Trial Highlights: - Mean weight loss of ~12.4% over 72 weeks for patients on the highest dose - Participants lost an average of 25 pounds (11.1%) regardless of trial completion - Safety profile consistent with GLP-1 class

Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generation obesity drugs, confirming a weight loss effect of up to 28% in phase 3 clinical trials

The prevalence of type 2 diabetes (T2D) is increasing worldwide

No direct link exists, but GI side effects may trigger flares

Our San Francisco and Palo Alto physicians explore how weight loss meds like semaglutide and tirzepatide have been shown to increase fertility